Grassi JM[au] - Search Results

Year	Number of Results
1998	5
1999	4
2001	1
2004	1
2006	2
2023	0

1

Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice.

von Moltke LL, Granda BW, Grassi JM, Perloff MD, Vishnuvardhan D, Greenblatt DJ. von Moltke LL, et al. Among authors: grassi jm. Drug Metab Dispos. 2004 Aug;32(8):800-4. doi: 10.1124/dmd.32.8.800. Drug Metab Dispos. 2004. PMID: 15258104

2

The effect of chronic lorazepam administration in aging mice.

Fahey JM, Pritchard GA, Reddi JM, Pratt JS, Grassi JM, Shader RI, Greenblatt DJ. Fahey JM, et al. Among authors: grassi jm. Brain Res. 2006 Nov 6;1118(1):13-24. doi: 10.1016/j.brainres.2006.08.017. Epub 2006 Sep 20. Brain Res. 2006. PMID: 16989785

3

Pharmacodynamic and receptor binding changes during chronic lorazepam administration.

Fahey JM, Pritchard GA, Grassi JM, Pratt JS, Shader RI, Greenblatt DJ. Fahey JM, et al. Among authors: grassi jm. Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):1-8. doi: 10.1016/s0091-3057(01)00507-x. Pharmacol Biochem Behav. 2001. PMID: 11420062

4

Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir.

von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, Shader RI. von Moltke LL, et al. Among authors: grassi jm. J Clin Pharmacol. 1998 Feb;38(2):106-11. doi: 10.1002/j.1552-4604.1998.tb04398.x. J Clin Pharmacol. 1998. PMID: 9549640

5

Acute zolpidem administration produces pharmacodynamic and receptor occupancy changes at similar doses.

Fahey JM, Grassi JM, Reddi JM, Greenblatt DJ. Fahey JM, et al. Among authors: grassi jm. Pharmacol Biochem Behav. 2006 Jan;83(1):21-7. doi: 10.1016/j.pbb.2005.12.006. Epub 2006 Jan 24. Pharmacol Biochem Behav. 2006. PMID: 16439007

6

Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations.

Von Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, Harmatz JS, Shader RI. Von Moltke LL, et al. Among authors: grassi jm. Br J Clin Pharmacol. 1999 Jul;48(1):89-97. doi: 10.1046/j.1365-2125.1999.00953.x. Br J Clin Pharmacol. 1999. PMID: 10383565 Free PMC article.

7

Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects.

von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Fogelman SM, Harmatz JS, Kramer SJ, Fabre LF, Shader RI. von Moltke LL, et al. Among authors: grassi jm. Psychopharmacology (Berl). 1998 Dec;140(3):293-9. doi: 10.1007/s002130050770. Psychopharmacology (Berl). 1998. PMID: 9877009

8

Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects.

von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Duan SX, Fogelman SM, Harmatz JS, Shader RI. von Moltke LL, et al. Among authors: grassi jm. Biol Psychiatry. 1999 Sep 15;46(6):839-49. doi: 10.1016/s0006-3223(98)00353-9. Biol Psychiatry. 1999. PMID: 10494454

9

Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice.

Fahey JM, Pritchard GA, Moltke LL, Pratt JS, Grassi JM, Shader RI, Greenblatt DJ. Fahey JM, et al. Among authors: grassi jm. J Pharmacol Exp Ther. 1998 Apr;285(1):271-6. J Pharmacol Exp Ther. 1998. PMID: 9536021

10

Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions.

von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, Shader RI. von Moltke LL, et al. Among authors: grassi jm. Psychopharmacology (Berl). 1999 Jul;145(1):113-22. doi: 10.1007/s002130051039. Psychopharmacology (Berl). 1999. PMID: 10445380

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results